Sorrento Therapeutics, Inc, a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease ...

10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever 0.0% of Sorrento Therapeutics shares are owned by institutional investors.

US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex Dividend Stock, previously distributed by Sorrento, to April 14, 2025.Accordingly ...

US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex Dividend Stock, previously distributed by Sorrento, to April 14, 2025.Accordingly, any ...

Shares in Sorrento Therapeutics rose 158% on Friday after it revealed plans to start human trials of an antibody therapy that achieved complete inhibition of the coronavirus in preclinical studies.

Health-Related Quality of Life for Persons Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions (AMC-A01) The management of renal cell carcinoma (RCC) has seen significant ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.